14-HN-25-AZ (D419300003) Combination of MEDI-4736 and tremelimumab in H&N cancer

Grants and Contracts Details

StatusFinished
Effective start/end date2/12/15 → 5/1/18

Funding

  • AstraZeneca Pharmaceuticals AB: $122,672.00